Clinical trial · Observational
Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. The investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (D-3MH) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples. In addition, the investigators hypothesize that ingestion of a meat-containing meal will stimulate synthesis of skeletal muscle proteins to a greater extent than a non-meat-containing meal.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- healthy control male
- label
- lung cancer male
Primary outcomes (1)
- measure
- Assessment of the slope of terminal D-3MH/3MH decay curve post-dosing.
- timeFrame
- Post-dosing 12 to 22 hours
- description
- Assess the slope of the terminal D-3MH/3MH decay curve for the post-dosing time period as calculated using plasma or urine samples and after a meat-containing or meat-free test meal.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * male * 30-85 years * Body Mass Index (BMI) \<30 kg/m2 Exclusion Criteria: * Uncontrolled hypertension * Glomerular filtration rate less than 60 mL/min/1.73 m2 * History of recurrent gastrointestinal bleeding * Unable or unwilling to provide informed consent * Ongoing anti-coagulant therapy
References
Publications (0)
Data not yet available